BioSpace News Archive

Moderna, Inc. , (Nasdaq: MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that it has submitted for authorization of its COVID-19 vaccine in adolescents with Health Canada.

Aeterna Zentaris Inc. (NASDAQ: AEZS) today announced it has engaged neuroimmunologist, Michael Levy, MD, PhD, as a scientific consultant to support the development of the Company’s targeted, highly specific immunosuppressive therapeutic proteins (“AIM Biologicals”) for the potential treatment of neuromyelitis optica spectrum disorder (“NMOSD”).

BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation treatments of mental health disorders, today announced the Company will participate in the upcoming global medical conferences:

Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced the appointment of Andrew Saik as Chief Financial Officer.

OliX Pharmaceuticals, Inc. (KOSDAQ: 226950), a leading developer of RNAi therapeutics, announced that the Company’s subsidiary mCureX has signed memorandums of understanding with Samyang Holdings to advance development of a messenger ribonucleic acid (mRNA) vaccine for COVID-19 and with GC Pharma to develop mRNA vaccines and therapeutics for respiratory infections and other diseases more broadly.

Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced that the Company will present at the Lytham Partners Summer 2021 Investor Conference.

MEI Pharma, Inc. (NASDAQ: MEIP), and Kyowa Kirin Co., Ltd. (Kyowa Kirin, TSE: 4151), today announced the dosing of the first patient with relapsed or refractory marginal zone lymphoma enrolled in the recently added second arm of the global Phase 2 TIDAL study of zandelisib,

Incisive Genetics Inc. (“IG”), a biotech company specializing in the research and development of a novel non-viral delivery platform for targeted CRISPR-based gene therapies, announced today the appointment of Kevin Chow, Ph.D. as President.

Exelixis, Inc. (NASDAQ: EXEL) and Ipsen (Euronext:IPN; ADR:IPSEY) today announced detailed results from the phase 3 COSMIC-311 pivotal trial of cabozantinib (CABOMETYX®) in patients with previously treated radioactive iodine-refractory differentiated thyroid cancer (DTC)

Humanigen, Inc. (Nasdaq: HGEN) (“Humanigen”), a clinical-stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine storm’ with its lead drug candidate, lenzilumab, today announced the appointment of Ken Trbovich to the newly-created role of SVP of Investor Relations